StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Investment analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners increased their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Down 2.1 %

Tonix Pharmaceuticals stock opened at $0.45 on Friday. The firm has a market cap of $7.81 million, a price-to-earnings ratio of 0.00 and a beta of 2.12. The firm has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $5.43. Tonix Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $32.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.47 and a quick ratio of 0.87.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,770,000 shares of the company’s stock after buying an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned 14.09% of Tonix Pharmaceuticals worth $1,519,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.